This website is for informational purposes only and does not constitute medical advice. Read disclaimer
Liraglutide
Based primarily on community reports and observational data
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management, predating semaglutide as the first GLP-1 agonist approved specifically for obesity.
Overview
Liraglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk with 97% homology to native human GLP-1. A fatty acid modification extends its half-life to approximately 13 hours for once-daily dosing. It pioneered the GLP-1 agonist class and paved the way for semaglutide.
FDA-approved in 2010 as Victoza for type 2 diabetes and in 2014 as Saxenda for weight management, liraglutide stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner. The SCALE trial program showed mean weight loss of approximately 8% with Saxenda, and the LEADER trial demonstrated cardiovascular benefits.
While surpassed by semaglutide in efficacy and public attention, liraglutide retains clinical importance. Its decade-plus safety record, pediatric obesity approval (Saxenda for ages 12+), and once-daily dosing maintain its relevance. It serves as an important option for patients who cannot tolerate newer agents.
Liraglutide also demonstrated a 79% reduction in progression from prediabetes to type 2 diabetes over 3 years, highlighting metabolic benefits beyond weight loss alone. Generic versions and biosimilars are beginning to reach the market.
## Key PubMed References
[1] Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)." N Engl J Med. 2015;373(1):11-22. PMID: 26132939
[2] Marso SP, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)." N Engl J Med. 2016;375(4):311-322. PMID: 27295427
[3] le Roux CW, et al. "3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management (SCALE)." Lancet. 2017;389(10077):1399-1409. PMID: 28237263
[4] Kelly AS, et al. "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity." N Engl J Med. 2020;382(22):2117-2128. PMID: 32233338
[5] Drucker DJ, Nauck MA. "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes." Lancet. 2006;368(9548):1696-1705. PMID: 17098089
